2023
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society.
Vukusic S, Carra-Dalliere C, Ciron J, Maillart E, Michel L, Leray E, Guennoc AM, Bourre B, Laplaud D, Androdias G, Bensa C, Bigaut K, Biotti D, Branger P, Casez O, Cohen M, Daval E, Deschamps R, Donze C, Dubessy AL, Dulau C, Durand-Dubief F, Guillaume M, Hebant B, Kremer L, Kwiatkowski A, Lannoy J, Maarouf A, Manchon E, Mathey G, Moisset X, Montcuquet A, Pique J, Roux T, Marignier R, Lebrun-Frenay C.
Mult Scler. 2023 Jan;29(1):11-36. doi: 10.1177/13524585221129472. Epub 2022 Nov 1.PMID: 36317497
Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society.
Vukusic S, Marignier R, Ciron J, Bourre B, Cohen M, Deschamps R, Guillaume M, Kremer L, Pique J, Carra-Dalliere C, Michel L, Leray E, Guennoc AM, Laplaud D, Androdias G, Bensa C, Bigaut K, Biotti D, Branger P, Casez O, Daval E, Donze C, Dubessy AL, Dulau C, Durand-Dubief F, Hebant B, Kwiatkowski A, Lannoy J, Maarouf A, Manchon E, Mathey G, Moisset X, Montcuquet A, Roux T, Maillart E, Lebrun-Frenay C.
Mult Scler. 2023 Jan;29(1):37-51. doi: 10.1177/13524585221130934. Epub 2022 Nov 8.PMID: 36345839
Facial emotion impairment in multiple sclerosis is linked to modifying observation strategies of emotional faces.
Polet K, Hesse S, Joly H, Cohen M, Morisot A, Kullmann B, Mondot L, Louchart de la Chapelle S, Pesce A, Lebrun-Frenay C.
Mult Scler Relat Disord. 2023 Jan;69:104439. doi: 10.1016/j.msard.2022.104439. Epub 2022 Dec 5.PMID: 36525898
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.
Sabathé C, Casey R, Vukusic S, Leray E, Mathey G, De Sèze J, Ciron J, Wiertlewski S, Ruet A, Pelletier J, Zéphir H, Michel L, Lebrun-Frenay C, Moisset X, Thouvenot E, Camdessanché JP, Bakchine S, Stankoff B, Al Khedr A, Cabre P, Maillart E, Berger E, Heinzlef O, Hankiewicz K, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Montcuquet A, Defer G, Maurousset A, Maubeuge N, Dimitri Boulos D, Ben Nasr H, Nifle C, Casez O, Laplaud DA, Foucher Y.
Mult Scler. 2023 Feb;29(2):236-247. doi: 10.1177/13524585221139156. Epub 2022 Dec 14.PMID: 36515394
Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease.
Carra-Dallière C, Rollot F, Deschamps R, Ciron J, Vukusic S, Audoin B, Ruet A, Maillart E, Papeix C, Zephir H, Laplaud D, Cohen M, Bourre B, El-Bahi I, Labauge P, Casey R, Ayrignac X, Marignier R.
Mult Scler. 2023 Feb;29(2):270-276. doi: 10.1177/13524585221134214. Epub 2022 Dec 1.PMID: 36453174
Sphingosine-1 Phosphate Receptor Modulators Increase In Vitro Melanoma Cell Line Proliferation at Therapeutic Doses Used in Patients with Multiple Sclerosis.
Ruetsch-Chelli C, Okuda DT, Rocher F, Tartare-Deckert S, Deckert M, Lebrun-Frenay C.
Neurol Ther. 2023 Feb;12(1):289-302. doi: 10.1007/s40120-022-00429-6. Epub 2022 Dec 16.PMID: 36534273
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis.
Garcia A, Dugast E, Shah S, Morille J, Lebrun-Frenay C, Thouvenot E, De Sèze J, Le Page E, Vukusic S, Maurousset A, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Bakdache F, Buffels R, Le Frère F, Nicot A, Wiertlewski S, Gourraud PA, Berthelot L, Laplaud D.
Neurol Neuroimmunol Neuroinflamm. 2023 Feb 21;10(3):e200091. doi: 10.1212/NXI.0000000000200091. Print 2023 May.PMID: 36810163
Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.
Okuda DT, Kantarci O, Lebrun-Frénay C, Sormani MP, Azevedo CJ, Bovis F, Hua LH, Amezcua L, Mowry EM, Hotermans C, Mendoza J, Walsh JS, von Hehn C, Vargas WS, Donlon S, Naismith RT, Okai A, Pardo G, Repovic P, Stüve O, Siva A, Pelletier D.
Ann Neurol. 2023 Mar;93(3):604-614. doi: 10.1002/ana.26555. Epub 2022 Dec 10.PMID: 36401339
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
Gavoille A, Rollot F, Casey R, Debouverie M, Le Page E, Ciron J, De Seze J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanche JP, Maurousset A, Moulin S, Ben NH, Boulos DD, Hankiewicz K, Neau JP, Pottier C, Nifle C, Rabilloud M, Subtil F, Vukusic S; Observatoire Français de la Sclérose en Plaques (OFSEP) Investigators.
Neurology. 2023 Mar 21;100(12):e1296-e1308. doi: 10.1212/WNL.0000000000206774. Epub 2022 Dec 23.PMID: 36564207
Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort.
Pelle J, Briant AR, Branger P, Derache N, Arnaud C, Lebrun-Frenay C, Cohen M, Mondot L, De Seze J, Bigaut K, Collongues N, Kremer L, Ricard D, Bompaire F, Ohlmann C, Sallansonnet-Froment M, Ciron J, Biotti D, Pignolet B, Parienti JJ, Defer G.
Neurol Ther. 2023 Apr;12(2):529-542. doi: 10.1007/s40120-023-00440-5. Epub 2023 Feb 10.PMID: 36763307
Comparing functional impact of multiple sclerosis on two populations in France, in the Caribbean Sea and in Europe, in regard of care level.
Thibault C, Jean-Etienne A, Lebrun-Frenay C, Cabre P, Drame M, Barnay JL.
Mult Scler Relat Disord. 2023 Apr;72:104559. doi: 10.1016/j.msard.2023.104559. Epub 2023 Mar 11.PMID: 36924582
Time to steroids impacts visual outcome of optic neuritis in MOGAD.
Rode J, Pique J, Maarouf A, Ayrignac X, Bourre B, Ciron J, Cohen M, Collongues N, Deschamps R, Maillart E, Montcuquet A, Papeix C, Ruet A, Wiertlewski S, Zephir H, Marignier R, Audoin B.
J Neurol Neurosurg Psychiatry. 2023 Apr;94(4):309-313. doi: 10.1136/jnnp-2022-330360. Epub 2022 Dec 13.PMID: 36600666
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis.
Januel E, Hajage D, Labauge P, Maillart E, De Sèze J, Zephir H, Pelletier J, Guilloton L, Bensa C, Heinzlef O, Casez O, Biotti D, Bourre B, Vukusic S, Maurousset A, Berger E, Laplaud D, Lebrun-Frénay C, Dubessy AL, Branger P, Thouvenot E, Clavelou P, Sellal F, Manchon E, Moreau T, Papeix C, Tubach F, Louapre C.
JAMA Netw Open. 2023 Jun 1;6(6):e2319766. doi: 10.1001/jamanetworkopen.2023.19766.PMID: 37351881
Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Yes.
Lebrun-Frenay C, Okuda DT.
Mult Scler. 2023 Jun;29(7):793-795. doi: 10.1177/13524585231172943. Epub 2023 May 22.PMID: 37212246
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Otero-Romero S, Lebrun-Frénay C, Reyes S, Amato MP, Campins M, Farez M, Filippi M, Hacohen Y, Hemmer B, Juuti R, Magyari M, Oreja-Guevara C, Siva A, Vukusic S, Tintoré M.
Mult Scler. 2023 Jul;29(8):904-925. doi: 10.1177/13524585231168043. Epub 2023 Jun 9.PMID: 37293841
Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.
Demuth S, Collongues N, Audoin B, Ayrignac X, Bourre B, Ciron J, Cohen M, Deschamps R, Durand-Dubief F, Maillart E, Papeix C, Ruet A, Zephir H, Marignier R, De Seze J; NOMADMUS Study Group.
Neurology. 2023 Jul 25;101(4):e438-e450. doi: 10.1212/WNL.0000000000207443. Epub 2023 Jun 8.PMID: 37290967
European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Otero-Romero S, Lebrun-Frénay C, Reyes S, Amato MP, Campins M, Farez M, Filippi M, Hacohen Y, Hemmer B, Juuti R, Magyari M, Oreja-Guevara C, Siva A, Vukusic S, Tintoré M.
Eur J Neurol. 2023 Aug;30(8):2144-2176. doi: 10.1111/ene.15809. Epub 2023 Jun 9.PMID: 37293849
Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.
Cohen M, Thomel-Rocchi O, Siva A, Okuda DT, Karabudak R, Efendi H, Terzi M, Carra-Dalliere C, Durand-Dubief F, Thouvenot E, Ciron J, Zephir H, Bourre B, Casez O, De Seze J, Moreau T, Neau JP, Pelletier D, Kantarci O, Tutuncu M, Derache N, Bensa C, Louapre C, Benoit J, Landes-Chateau C, Lebrun-Frenay C.
Mult Scler. 2023 Aug;29(9):1099-1106. doi: 10.1177/13524585231179669. Epub 2023 Jun 15.PMID: 37322880
The radiologically isolated syndrome: revised diagnostic criteria.
Lebrun-Frénay C, Okuda DT, Siva A, Landes-Chateau C, Azevedo CJ, Mondot L, Carra-Dallière C, Zephir H, Louapre C, Durand-Dubief F, Le Page E, Bensa C, Ruet A, Ciron J, Laplaud DA, Casez O, Mathey G, de Seze J, Zeydan B, Makhani N, Tutuncu M, Levraut M, Cohen M, Thouvenot E, Pelletier D, Kantarci OH.
Brain. 2023 Aug 1;146(8):3431-3443. doi: 10.1093/brain/awad073.PMID: 36864688
Kappa Free Light Chain Index Predicts Disease Course in Clinically and Radiologically Isolated Syndromes.
Levraut M, Gavoille A, Landes-Chateau C, Cohen M, Bresch S, Seitz-Polski B, Mondot L, Lebrun-Frenay C.
Neurol Neuroimmunol Neuroinflamm. 2023 Aug 28;10(6):e200156. doi: 10.1212/NXI.0000000000200156. Print 2023 Nov.PMID: 37640543
Letter to the editor on "new algorithmic approach for easier and faster extended disability status scale calculation".
Cohen M, Lebrun Frenay C.
Mult Scler J Exp Transl Clin. 2023 Aug 30;9(3):20552173231192941. doi: 10.1177/20552173231192941. eCollection 2023 Jul-Sep.PMID: 37655136
The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers.
Brocard G, Casey R, Dufay N, Marignier R, Michel L, Hisbergues M, Ayrignac X, Lehmann S, Thouvenot E, Gallot G, Collongues N, Herpe YE, Lebrun-Frenay C, Cotton F, De Sèze J, Guillemin F, Moreau T, Pelletier J, Stankoff B, Vukusic S, Zephir H, Laplaud D; OFSEP investigators and biobanks.
Mult Scler Relat Disord. 2023 Sep;77:104872. doi: 10.1016/j.msard.2023.104872. Epub 2023 Jul 7.PMID: 37453261
Towards a more precise rating of neurological disability in multiple sclerosis: A new automatic and linear quantification of limbs function.
Cohen M, Mondot L, Landes-Chateau C, Lebrun-Frenay C.
Mult Scler Relat Disord. 2023 Sep;77:104904. doi: 10.1016/j.msard.2023.104904. Epub 2023 Jul 20.PMID: 37480737
Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.
Lebrun-Frénay C, Siva A, Sormani MP, Landes-Chateau C, Mondot L, Bovis F, Vermersch P, Papeix C, Thouvenot E, Labauge P, Durand-Dubief F, Efendi H, Le Page E, Terzi M, Derache N, Bourre B, Hoepner R, Karabudak R, De Seze J, Ciron J, Clavelou P, Wiertlewski S, Turan OF, Yucear N, Cohen M, Azevedo C, Kantarci OH, Okuda DT, Pelletier D; TERIS Study Group.
JAMA Neurol. 2023 Oct 1;80(10):1080-1088. doi: 10.1001/jamaneurol.2023.2815.PMID: 37603328
Comparison of Two Methods for Estimating MS-Related Mortality: The Excess Mortality vs. the Cause-Specific Frameworks.
Rollot F, Uhry Z, Dantony E, Vukusic S, Debouverie M, Le Page E, Ciron J, Ruet A, De Seze J, Zephir H, Labauge PM, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Clavelou P, Pelletier J, Thouvenot E, Heinzlef O, Camdessanche JP, Fauvernier M, Remontet L, Leray E.
Neurology. 2023 Oct 12:10.1212/WNL.0000000000207925. doi: 10.1212/WNL.0000000000207925. Online ahead of print.PMID: 37827849
Radiologically isolated syndrome.
Lebrun-Frenay C, Kantarci O, Siva A, Azevedo CJ, Makhani N, Pelletier D, Okuda DT.
Lancet Neurol. 2023 Nov;22(11):1075-1086. doi: 10.1016/S1474-4422(23)00281-8. Epub 2023 Oct 12.PMID: 37839432
Reply: Do we need new MRI criteria for the diagnosis of radiologically isolated syndrome?
Lebrun-Frenay C, Kantarci OH, Siva A, Pelletier D, Okuda DT.
Brain. 2023 Nov 2;146(11):e104-e106. doi: 10.1093/brain/awad186.PMID: 37259177
2022
Glial Fibrillary Acidic Protein (GFAP) Astrocytopathy Presenting as Mild Encephalopathy with Reversible Splenium Lesion.
Héraud C, Capet N, Levraut M, Hattenberger R, Bourg V, Thomas P, Mondot L, Lebrun-Frenay C.
Neurol Ther. 2022 Mar;11(1):499-505. doi: 10.1007/s40120-021-00302-y. Epub 2021 Nov 29.PMID: 34843090
Marburg Multiple Sclerosis Variant: Complete Remission with Very Early Administration of Mitoxantrone-A Case Report.
Capet N, Levraut M, Delourme A, Thomel-Rocchi O, Bourg V, Cabre P, Vandenbos F, Mondot L, Lebrun-Frenay C.
Neurol Ther. 2022 Mar;11(1):507-513. doi: 10.1007/s40120-021-00308-6. Epub 2021 Dec 2.PMID: 34859363
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.
Rollot F, Couturier J, Casey R, Wiertlewski S, Debouverie M, Pelletier J, De Sèze J, Labauge P, Ruet A, Thouvenot E, Ciron J, Berger E, Gout O, Clavelou P, Stankoff B, Casez O, Bourre B, Zephir H, Moreau T, Lebrun-Frenay C, Maillart E, Edan G, Neau JP, Montcuquet A, Cabre P, Camdessanché JP, Defer G, Nasr HB, Maurousset A, Hankiewicz K, Pottier C, Leray E, Vukusic S, Laplaud DA.
Neurotherapeutics. 2022 Mar;19(2):476-490. doi: 10.1007/s13311-022-01202-1. Epub 2022 Feb 25.PMID: 35217934
Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.
Demuth S, Guillaume M, Bourre B, Ciron J, Zephir H, Sirejacob Y, Kerbrat A, Lebrun-Frenay C, Papeix C, Michel L, Laplaud D, Vukusic S, Maillart E, Cohen M, Audoin B, Marignier R, Collongues N; NOMADMUS Study Group.
J Neuroinflammation. 2022 Mar 2;19(1):62. doi: 10.1186/s12974-022-02420-2.PMID: 35236386
Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities.
Levraut M, Landes C, Mondot L, Cohen M, Bresch S, Brglez V, Seitz-Polski B, Lebrun-Frenay C.
Front Immunol. 2022 Mar 25;13:864133. doi: 10.3389/fimmu.2022.864133. eCollection 2022.PMID: 35401550
Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.
Papeix C, Castelnovo G, Leray E, Coustans M, Levy P, Visy JM, Kobelt G, Lamy F, Allaf B, Heintzmann F, Chouette I, Raponi E, Durand B, Grevat E, Kamar D, Debouverie M, Lebrun-Frenay C; Virgile Study Group.
Neurol Ther. 2022 Jun;11(2):633-658. doi: 10.1007/s40120-022-00334-y. Epub 2022 Feb 11.PMID: 35147904
Peripheral facial palsy following COVID-19 vaccination: a practical approach to use the clinical situation as a guide.
Foirest C, Bihan K, Tankéré F, Junot H, Demeret S, Debs R, Maillart E, Lebrun-Frenay C, Vigouroux A, Caudron M, Canouï E, Lamas G, Weiss N, Pourcher V.
Acta Otorhinolaryngol Ital. 2022 Jun;42(3):300-303. doi: 10.14639/0392-100X-N2131.PMID: 35880371
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, Gouider R, Hacohen Y, Hellwig K, Hemmer B, Kappos L, Ladeira F, Lebrun-Frénay C, Louapre C, Magyari M, Mehling M, Oreja-Guevara C, Pandit L, Papeix C, Piehl F, Portaccio E, Ruiz-Camps I, Selmaj K, Simpson-Yap S, Siva A, Sorensen PS, Sormani MP, Trojano M, Vaknin-Dembinsky A, Vukusic S, Weinshenker B, Wiendl H, Winkelmann A, Zuluaga Rodas MI, Tintoré M, Stankoff B.
Mult Scler. 2022 Aug;28(9):1424-1456. doi: 10.1177/13524585211069068. Epub 2022 Feb 23.PMID: 35196927
Reliability of mobile video-oculography in multiple sclerosis patients using an iPad: A prospective validation study.
Cohen M, Hesse S, Polet K, Louchart de la Chapelle S, Morisot A, Bresch S, Pesce A, Lebrun-Frenay C.
Mult Scler Relat Disord. 2022 Aug;64:103944. doi: 10.1016/j.msard.2022.103944. Epub 2022 Jun 6.PMID: 35679780
From the prodromal stage of multiple sclerosis to disease prevention.
Marrie RA, Allegretta M, Barcellos LF, Bebo B, Calabresi PA, Correale J, Davis B, De Jager PL, Gasperi C, Greenbaum C, Helme A, Hemmer B, Kanellis P, Kostich W, Landsman D, Lebrun-Frenay C, Makhani N, Munger KL, Okuda DT, Ontaneda D, Postuma RB, Quandt JA, Roman S, Saidha S, Sormani MP, Strum J, Valentine P, Walton C, Zackowski KM, Zhao Y, Tremlett H.
Nat Rev Neurol. 2022 Sep;18(9):559-572. doi: 10.1038/s41582-022-00686-x. Epub 2022 Jul 15.PMID: 35840705
COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients.
Leguy S, Lefort M, Lescot L, Michaud A, Vukusic S, Le Page E, Edan G, Kerbrat A, Lebrun-Frenay C, De Sèze J, Laplaud DA, Wiertlewski S, Leray E, Michel L.
J Neurol. 2022 Oct;269(10):5571-5581. doi: 10.1007/s00415-022-11215-7. Epub 2022 Jun 23.PMID: 35737108
Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome.
Rival M, Thouvenot E, Du Trieu de Terdonck L, Laurent-Chabalier S, Demattei C, Uygunoglu U, Castelnovo G, Cohen M, Okuda DT, Kantarci OH, Pelletier D, Azevedo C, Marin P, Lehmann S, Siva A, Mura T, Lebrun-Frenay C; SFSEP and RISC.
Neurol Neuroimmunol Neuroinflamm. 2022 Oct 24;10(1):e200044. doi: 10.1212/NXI.0000000000200044. Print 2023 Jan.PMID: 36280258
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Roos I, Malpas C, Leray E, Casey R, Horakova D, Havrdova EK, Debouverie M, Patti F, De Seze J, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Ozakbas S, Grammond P, Zephir H, Ciron J, Maillart E, Moreau T, Amato MP, Labauge P, Alroughani R, Buzzard K, Skibina O, Terzi M, Laplaud DA, Berger E, Grand'Maison F, Lebrun-Frenay C, Cartechini E, Boz C, Lechner-Scott J, Clavelou P, Stankoff B, Prevost J, Kappos L, Pelletier J, Shaygannejad V, Yamout BI, Khoury SJ, Gerlach O, Spitaleri DLA, Van Pesch V, Gout O, Turkoglu R, Heinzlef O, Thouvenot E, McCombe PA, Soysal A, Bourre B, Slee M, Castillo-Trivino T, Bakchine S, Ampapa R, Butler EG, Wahab A, Macdonell RA, Aguera-Morales E, Cabre P, Ben NH, Van der Walt A, Laureys G, Van Hijfte L, Ramo-Tello CM, Maubeuge N, Hodgkinson S, Sánchez-Menoyo JL, Barnett MH, Labeyrie C, Vucic S, Sidhom Y, Gouider R, Csepany T, Sotoca J, de Gans K, Al-Asmi A, Fragoso YD, Vukusic S, Butzkueven H, Kalincik T; MSBase and OFSEP.
Neurology. 2022 Oct 25;99(17):e1926-e1944. doi: 10.1212/WNL.0000000000201029. Epub 2022 Aug 17.PMID: 35977837
Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study.
Levraut M, Laurent-Chabalier S, Ayrignac X, Bigaut K, Rival M, Squalli S, Zéphir H, Alberto T, Pekar JD, Ciron J, Biotti D, Puissant-Lubrano B, Camdessanché JP, Tholance Y, Casez O, Toussaint B, Marion J, Moreau T, Lakomy D, Thomasset A, Maillart E, Sterlin D, Maurousset A, Rocher A, Laplaud DA, Bigot-Corbel E, Bertho PO, Pelletier J, Boucraut J, Labauge P, Vincent T, De Sèze J, Jahn I, Seitz-Polski B, Thouvenot E, Lebrun-Frenay C; Société Francophone de la Sclérose En Plaques (SFSEP).
Neurol Neuroimmunol Neuroinflamm. 2022 Nov 14;10(1):e200049. doi: 10.1212/NXI.0000000000200049. Print 2023 Jan.PMID: 36376096
Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study.
Wilson S, Calocer F, Rollot F, Fauvernier M, Remontet L, Tron L, Vukusic S, Le Page E, Debouverie M, Ciron J, Ruet A, De Sèze J, Zephir H, Moreau T, Lebrun-Frénay C, Laplaud DA, Clavelou P, Labauge P, Berger E, Pelletier J, Heinzlef O, Thouvenot E, Camdessanché JP, Leray E, Dejardin O, Defer G.
Lancet Reg Health Eur. 2022 Nov 17;24:100542. doi: 10.1016/j.lanepe.2022.100542. eCollection 2023 Jan.PMID: 36426377
Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E, Laplaud D, Vukusic S, Labauge P, Moreau T, Kobelt G, Grouin JM, Lotz M, Pau D, Christine LF.
Mult Scler Relat Disord. 2022 Dec;68:104109. doi: 10.1016/j.msard.2022.104109. Epub 2022 Aug 13.PMID: 36007299
Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients.
Lescot L, Lefort M, Leguy S, Le Page E, Vukusic S, Edan G, Kerbrat A, Lebrun-Frenay C, De Sèze J, Laplaud DA, Wiertlewski S, Leray E, Michel L.
Mult Scler Relat Disord. 2022 Dec;68:104122. doi: 10.1016/j.msard.2022.104122. Epub 2022 Aug 15.PMID: 36037756
2021
Association of Immunosuppression and Viral Load With Subcortical Brain Volume in an International Sample of People Living With HIV.
Nir TM, Fouche JP, Ananworanich J, Ances BM, Boban J, Brew BJ, Chaganti JR, Chang L, Ching CRK, Cysique LA, Ernst T, Faskowitz J, Gupta V, Harezlak J, Heaps-Woodruff JM, Hinkin CH, Hoare J, Joska JA, Kallianpur KJ, Kuhn T, Lam HY, Law M, Lebrun-Frénay C, Levine AJ, Mondot L, Nakamoto BK, Navia BA, Pennec X, Porges EC, Salminen LE, Shikuma CM, Surento W, Thames AD, Valcour V, Vassallo M, Woods AJ, Thompson PM, Cohen RA, Paul R, Stein DJ, Jahanshad N.
JAMA Netw Open. 2021 Jan 4;4(1):e2031190. doi: 10.1001/jamanetworkopen.2020.31190.PMID: 33449093
Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, Papeix C, Audoin B, Lépine AF, Maurey H, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Meyer P, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Horello P, Tintoré M, De Seze J, Vukusic S, Deiva K, Marignier R; NOMADMUS, KidBioSEP, and OFSEP study groups.
Ann Neurol. 2021 Jan;89(1):30-41. doi: 10.1002/ana.25909. Epub 2020 Oct 15.PMID: 32959427
Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis.
Mathais S, Moisset X, Pereira B, Taithe F, Ciron J, Labauge P, Dulau C, Laplaud D, De Seze J, Pelletier J, Berger E, Lebrun-Frenay C, Castelnovo G, Edan G, Defer G, Vermersch P, Bourre B, Camdessanche JP, Magy L, Guennoc AM, Mathey G, Moreau T, Gout O, Heinzlef O, Maillart E, Vukusic S, Clavelou P; SFSEP and OFSEP investigators.
Neurotherapeutics. 2021 Jan;18(1):378-386. doi: 10.1007/s13311-020-00926-2. Epub 2020 Sep 22.PMID: 32964402
Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like Syndrome.
Taieb G, Kaphan E, Duflos C, Lebrun-Frénay C, Rigau V, Thouvenot E, Duhin-Gand E, Lefaucheur R, Hoang-Xuan K, Coulette S, Ouallet JC, Menjot de Champfleur N, Tranchant C, Picard C, Fusaro M, Sepulveda FE, Labauge P, de Saint Basile G.
Neurol Neuroimmunol Neuroinflamm. 2021 Mar 3;8(3):e970. doi: 10.1212/NXI.0000000000000970. Print 2021 May.PMID: 33658321
Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis.
Ruetsch-Chelli C, Bresch S, Seitz-Polski B, Rosenthal A, Desnuelle C, Cohen M, Brglez V, Ticchioni M, Lebrun-Frenay C.
Neurotherapeutics. 2021 Apr;18(2):938-948. doi: 10.1007/s13311-021-01006-9. Epub 2021 Mar 25.PMID: 33768513
Digital biomarkers can highlight subtle clinical differences in radiologically isolated syndrome compared to healthy controls.
Cohen M, Mondot L, Fakir S, Landes C, Lebrun C.
J Neurol. 2021 Apr;268(4):1316-1322. doi: 10.1007/s00415-020-10276-w. Epub 2020 Oct 19.PMID: 33078309
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
Fissolo N, Pignolet B, Rio J, Vermersch P, Ruet A, deSèze J, Labauge P, Vukusic S, Papeix C, Martinez-Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Bourre B, Defer G, Montalban X, Brassat D, Comabella M.
Neurol Neuroimmunol Neuroinflamm. 2021 Apr 26;8(4):e1003. doi: 10.1212/NXI.0000000000001003. Print 2021 Jul.PMID: 33903203
Comparison of SimoaTM and EllaTM to assess serum neurofilament-light chain in multiple sclerosis.Gauthier A, Viel S, Perret M, Brocard G, Casey R, Lombard C, Laurent-Chabalier S, Debouverie M, Edan G, Vukusic S, Lebrun-Frénay C, De Sèze J, Laplaud DA, Castelnovo G, Gout O, Ruet A, Moreau T, Casez O, Clavelou P, Berger E, Zephir H, Trouillet-Assant S, Thouvenot E; OFSEP Investigators.
Ann Clin Transl Neurol. 2021 May;8(5):1141-1150. doi: 10.1002/acn3.51355. Epub 2021 Apr 8.PMID: 33830650
The long-term outcome of MOGAD: An observational national cohort study of 61 patients.
Deschamps R, Pique J, Ayrignac X, Collongues N, Audoin B, Zéphir H, Ciron J, Cohen M, Aboab J, Mathey G, Derache N, Laplaud D, Thouvenot E, Bourre B, Ruet A, Durand-Dubief F, Touitou V, Vignal-Clermont C, Papeix C, Gout O, Marignier R, Maillart E; NOMADMUS study group.
Eur J Neurol. 2021 May;28(5):1659-1664. doi: 10.1111/ene.14746. Epub 2021 Feb 19.PMID: 33528851
Cerebrospinal Fluid IL-17A Could Predict Acute Disease Severity in Non-NMDA-Receptor Autoimmune Encephalitis.
Levraut M, Bourg V, Capet N, Delourme A, Honnorat J, Thomas P, Lebrun-Frenay C.
Front Immunol. 2021 May 13;12:673021. doi: 10.3389/fimmu.2021.673021. eCollection 2021.PMID: 34054854
MRI findings in blinded trials should be available to treating physicians - Yes.
Vukusic S, Lebrun-Frenay C.
Mult Scler. 2021 May;27(6):812-813. doi: 10.1177/1352458520984744. Epub 2021 Mar 29.PMID: 33779365
Vaccinations in multiple sclerosis patients receiving disease-modifying drugs.
Otero-Romero S, Ascherio A, Lebrun-Frénay C.
Curr Opin Neurol. 2021 Jun 1;34(3):322-328. doi: 10.1097/WCO.0000000000000929.PMID: 33709979
Untreated patients with multiple sclerosis: A study of French expert centers.
Moisset X, Fouchard AA, Pereira B, Taithe F, Mathey G, Edan G, Ciron J, Brochet B, De Sèze J, Papeix C, Vermersch P, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Laplaud D, Berger E, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Créange A, Camdessanché JP, Bakchine S, Maurousset A, Hankiewicz K, Pottier C, Maubeuge N, Dimitri Boulos D, Nifle C, Vukusic S, Clavelou P; OFSEP investigators.
Eur J Neurol. 2021 Jun;28(6):2026-2036. doi: 10.1111/ene.14790. Epub 2021 Mar 19.PMID: 33650261
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP).
Bigaut K, Cohen M, Durand-Dubief F, Maillart E, Planque E, Zephir H, Lebrun-Frenay C, de Seze J; French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Française de la Sclérose En Plaques (SFSEP).
Mult Scler Relat Disord. 2021 Aug;53:103076. doi: 10.1016/j.msard.2021.103076. Epub 2021 Jun 10.PMID: 34161898
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
Vukusic S, Ionescu I, Cornu C, Bossard N, Durand-Dubief F, Cotton F, Durelli L, Marignier R, Gignoux L, Laplaud DA, Moreau T, Clavelou P, De Seze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Trojano M, Patti F, Baulieu EE, Remontet L, El-Etr M.
Mult Scler. 2021 Aug;27(9):1458-1463. doi: 10.1177/1352458520978218. Epub 2020 Dec 3.PMID: 33269975
Should we still only rely on EDSS to evaluate disability in multiple sclerosis patients? A study of inter and intra rater reliability.
Cohen M, Bresch S, Thommel Rocchi O, Morain E, Benoit J, Levraut M, Fakir S, Landes C, Lebrun-Frénay C.
Mult Scler Relat Disord. 2021 Sep;54:103144. doi: 10.1016/j.msard.2021.103144. Epub 2021 Jul 9.PMID: 34274736
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
Cohen M, Mondot L, Bucciarelli F, Pignolet B, Laplaud DA, Wiertlewski S, Brochet B, Ruet A, Defer G, Derache N, Vermersch P, Zephir H, Debouverie M, Mathey G, Berger E, Cappé C, Labauge P, Carra C, De Seze J, Bigaut K, Brassat D, Lebrun-Frenay C.
Mult Scler. 2021 Sep;27(10):1556-1563. doi: 10.1177/1352458520969145. Epub 2020 Oct 30.PMID: 33124504
The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients - No.
Tremlett H, Okuda DT, Lebrun-Frenay C.
Mult Scler. 2021 Oct;27(12):1824-1826. doi: 10.1177/13524585211035951. Epub 2021 Sep 8.PMID: 34494923
MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis.
Tanoh IC, Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, Donzé C, Gallien P, De Sèze J, Bourre B, Moreau T, Louapre C, Vallée M, Bieuvelet S, Klaeylé L, Argoud AL, Zinaï S, Tourbah A.
Mult Scler Relat Disord. 2021 Oct;55:103164. doi: 10.1016/j.msard.2021.103164. Epub 2021 Jul 23.PMID: 34352512
A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.
Giovannelli J, Ciron J, Cohen M, Kim HJ, Kim SH, Stellmann JP, Kleiter I, McCreary M, Greenberg BM, Deschamps R, Audoin B, Maillart E, Papeix C, Collongues N, Bourre B, Laplaud D, Ayrignac X, Durand-Dubief F, Ruet A, Vukusic S, Marignier R, Dauchet L, Zephir H; NEMOS (Neuromyelitis Optica Study Group in Germany), NOMADMUS (Neuromyelitis Optica study Group in France), OFSEP (Observatoire Français de la Sclérose en Plaques) investigators.
Ann Clin Transl Neurol. 2021 Oct;8(10):2025-2037. doi: 10.1002/acn3.51451. Epub 2021 Sep 10.PMID: 34505407
Determinants of therapeutic lag in multiple sclerosis.
Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Debouverie M, Trojano M, Patti F, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grammond P, Ciron J, Ruet A, Ozakbas S, De Seze J, Louapre C, Zephir H, Sá MJ, Sola P, Ferraro D, Labauge P, Defer G, Bergamaschi R, Lebrun-Frenay C, Boz C, Cartechini E, Moreau T, Laplaud D, Lechner-Scott J, Grand'Maison F, Gerlach O, Terzi M, Granella F, Alroughani R, Iuliano G, Van Pesch V, Van Wijmeersch B, Spitaleri D, Soysal A, Berger E, Prevost J, Aguera-Morales E, McCombe P, Castillo Triviño T, Clavelou P, Pelletier J, Turkoglu R, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Sidhom Y, Gouider R, Csepany T, Bourre B, Al Khedr A, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanche JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Coles A, Malpas CB, Vukusic S, Butzkueven H, Kalincik T.
Mult Scler. 2021 Oct;27(12):1838-1851. doi: 10.1177/1352458520981300. Epub 2021 Jan 11.PMID: 33423618
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome.
Lebrun-Frénay C, Rollot F, Mondot L, Zephir H, Louapre C, Le Page E, Durand-Dubief F, Labauge P, Bensa C, Thouvenot E, Laplaud D, de Seze J, Ciron J, Bourre B, Cabre P, Casez O, Ruet A, Mathey G, Berger E, Moreau T, Al Khedr A, Derache N, Clavelou P, Guennoc AM, Créange A, Neau JP, Tourbah A, Camdessanché JP, Maarouf A, Callier C, Vermersch P, Kantarci O, Siva A, Azevedo C, Makhani N, Cohen M, Pelletier D, Okuda D, Vukusic S; RISC, SFSEP, and OFSEP Investigators.
JAMA Netw Open. 2021 Oct 1;4(10):e2128271. doi: 10.1001/jamanetworkopen.2021.28271.PMID: 34633424
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S, Lefort M, Andersen JB, Leray E, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frénay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Laplaud D, Koch-Henriksen N, Sellebjerg FT, Soerensen PS, Pfleger CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Magyari M, Vukusic S, Butzkueven H, Kalincik T; Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators.
CNS Drugs. 2021 Nov;35(11):1217-1232. doi: 10.1007/s40263-021-00860-7. Epub 2021 Sep 18.PMID: 34536228
CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments.
Bernard-Valnet R, Moisset X, Maubeuge N, Lefebvre M, Ouallet JC, Roumier M, Lebrun-Frenay C, Ciron J, Biotti D, Clavelou P, Godeau B, Du Pasquier RA, Martin-Blondel G.
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 2;9(1):e1097. doi: 10.1212/NXI.0000000000001097. Print 2022 Jan.PMID: 34728496
Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
Papeix C, Mazoyer J, Maillart E, Bensa C, Dubessy AL, Goujon C, Launay O, Lebrun-Frénay C, Louapre C, Mrejen S, Pourcher V, Rosenheim M, Stankoff B, Vidal JS, Lubetzki C.
Mult Scler. 2021 Dec;27(14):2280-2283. doi: 10.1177/13524585211006372. Epub 2021 Apr 19.PMID: 33870792
2020
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, Edan G, Brassat D, Ruet A, De Sèze J, Maillart E, Zéphir H, Labauge P, Derache N, Lebrun-Frenay C, Moreau T, Wiertlewski S, Berger E, Moisset X, Rico-Lamy A, Stankoff B, Bensa C, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Vaillant M, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Tourbah A, Guennoc AM, Hankiewicz K, Patry I, Nifle C, Maubeuge N, Labeyrie C, Vermersch P, Laplaud DA; OFSEP Investigators.
JAMA Neurol. 2020 Jan 1;77(1):94-102. doi: 10.1001/jamaneurol.2019.2670.PMID: 31479149
Validation of a rapid and easy-to-perform screening test for neurocognitive impairment in HIV+ patients.
Joly H, Vassallo M, Issaurat M, Fabre R, Pradier C, Lebrun-Frenay C.
J Neurol Sci. 2020 Mar 15;410:116664. doi: 10.1016/j.jns.2019.116664. Epub 2019 Dec 28.PMID: 31911282
Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies.
Maillart E, Durand-Dubief F, Louapre C, Audoin B, Bourre B, Derache N, Ciron J, Collongues N, de Sèze J, Cohen M, Lebrun-Frenay C, Hadhoum N, Zéphir H, Deschamps R, Carra-Dallière C, Labauge P, Kerschen P, Montcuquet A, Wiertlewski S, Laplaud D, Runavot G, Vukusic S, Papeix C, Marignier R; OFSEP, SFSEP, and NOMADMUS study groups.
J Neuroinflammation. 2020 Apr 23;17(1):128. doi: 10.1186/s12974-020-01773-w.PMID: 32326965
Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.
Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, Collongues N, Deschamps R, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Zephir H, Bereau M, Brochet B, Carra-Dallière C, Derache N, Gagou-Scherer C, Henry C, Kerschen P, Mathey G, Maubeuge N, Maurousset A, Montcuquet A, Moreau T, Prat C, Taithe F, Thouvenot E, Tourbah A, Rollot F, Vukusic S, Marignier R.
Mult Scler. 2020 Jul;26(8):936-944. doi: 10.1177/1352458519849511. Epub 2019 May 31.PMID: 31148523
Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event.
Lebrun-Frenay C, Kantarci O, Siva A, Sormani MP, Pelletier D, Okuda DT; 10-year RISC study group on behalf of SFSEP, OFSEP.
Ann Neurol. 2020 Aug;88(2):407-417. doi: 10.1002/ana.25799. Epub 2020 Jun 29.PMID: 32500558
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
Vukusic S, Ionescu I, Cornu C, Bossard N, Durand-Dubief F, Cotton F, Durelli L, Marignier R, Gignoux L, Laplaud DA, Moreau T, Clavelou P, De Seze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Trojano M, Patti F, Baulieu EE, Remontet L, El-Etr M.
Mult Scler. 2021 Aug;27(9):1458-1463. doi: 10.1177/1352458520978218. Epub 2020 Dec 3.PMID: 33269975
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, Deschamps R, Créange A, Wahab A, Pelletier J, Heinzlef O, Labauge P, Guilloton L, Ahle G, Goudot M, Bigaut K, Laplaud DA, Vukusic S, Lubetzki C, De Sèze J; Covisep investigators; Derouiche F, Tourbah A, Mathey G, Théaudin M, Sellal F, Dugay MH, Zéphir H, Vermersch P, Durand-Dubief F, Françoise R, Androdias-Condemine G, Pique J, Codjia P, Tilikete C, Marcaud V, Lebrun-Frenay C, Cohen M, Ungureanu A, Maillart E, Beigneux Y, Roux T, Corvol JC, Bordet A, Mathieu Y, Le Breton F, Boulos DD, Gout O, Guéguen A, Moulignier A, Boudot M, Chardain A, Coulette S, Manchon E, Ayache SS, Moreau T, Garcia PY, Kumaran D, Castelnovo G, Thouvenot E, Taithe F, Poupart J, Kwiatkowski A, Defer G, Derache N, Branger P, Biotti D, Ciron J, Clerc C, Vaillant M, Magy L, Montcuquet A, Kerschen P, Coustans M, Guennoc AM, Brochet B, Ouallet JC, Ruet A, Dulau C, Wiertlewski S, Berger E, Buch D, Bourre B, Pallix-Guiot M, Maurousset A, Audoin B, Rico A, Maarouf A, Edan G, Papassin J, Videt D.
JAMA Neurol. 2020 Sep 1;77(9):1079-1088. doi: 10.1001/jamaneurol.2020.2581.PMID: 32589189
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients.
Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, Brandt A, Berek K, Berger T, Jelcic I, Gombolay G, Oliveira LM, Callegaro D, Kaneko K, Misu T, Capobianco M, Gibbons E, Karthikeayan V, Broc
